RET and non-small cell lung carcinoma: Interim results from a Phase I clinical trial of 79 RET fusion-positive NSCLC patients treated with BLU-677 demonstrated an ORR of 56% among the 57 evaluable patients and encouraging central nervous system (CNS) activity against brain metastases [127].